+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate treatments for adult men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC who have previously received androgen receptor pathway inhibitors, taxane-based chemotherapy, and progressed on or after 177LuLu-PSMA targeted therapy. The study includes both Phase II and Phase III portions to gather detailed information on dosing and to compare the investigational treatment AAA817 with standard care. Participants will be randomly assigned to receive either AAA817, given in cycles of 8 weeks, or the investigators choice of standard of care treatment. The Phase II part focuses on supporting the dose of AAA817, while the Phase III part compares the efficacy and safety of AAA817 against standard treatments. The study is open-label and conducted internationally across multiple centers. During the study, participants will be monitored for biochemical responses, adverse events, and disease progression through imaging scans and clinical assessments over approximately 24 months. The research team will track survival rates, disease control, patient-reported symptoms, and quality of life. Safety and tolerability of AAA817 will be evaluated from the start of treatment until several weeks after the last dose. Overall, the study spans several years, including follow-up periods to assess long-term outcomes.

Age: 18Years - 100YearsMALEPhase 2Phase 3
93 locations
L

Actively Recruiting

This research aims to evaluate the effectiveness of a structured lifestyle intervention to induce remission of Type 2 Diabetes Mellitus T2DM among Malaysian adults. It also assesses the feasibility of implementing this approach within Malaysian primary and specialist care settings and examines the economic impact through cost-effectiveness analysis from a societal perspective. The study compares intensive lifestyle intervention to usual clinical care, hypothesizing higher diabetes remission rates, greater weight loss, better blood sugar control, and improved cost-effectiveness for those receiving the intervention. The trial uses a randomized, wait-list-controlled design with two phases. In the first phase, participants are randomly assigned to either an immediate intervention group or a wait-list control group. The intervention group undergoes a total diet replacement TDR phase for 8 to 12 weeks with a low-calorie diet, followed by a food reintroduction phase lasting 12 to 16 weeks, and then a 24-week weight maintenance phase. The wait-list control group receives usual care for 24 weeks before crossing over to the intervention. Medical management includes careful medication withdrawal and reintroduction protocols to manage blood pressure and blood sugar levels. Participants attend face-to-face or virtual appointments and phone calls with dietitians throughout the study. They complete food records and consumption logs to monitor adherence. The study measures diabetes remission rates at 6 months as the primary outcome, with secondary outcomes including remission maintenance at 12 months, weight loss, insulin resistance, and pancreatic function. Safety is monitored through regular checks of blood pressure, symptoms, and blood glucose levels, with adverse events reported promptly. The total participation period includes initial intervention and follow-up phases lasting up to 12 months.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
2 locations